OncoSil Medical Management
Management criteria checks 1/4
OncoSil Medical's CEO is Nigel Lange, appointed in Jan 2021, has a tenure of 3.33 years. total yearly compensation is A$638.57K, comprised of 60.8% salary and 39.2% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth A$40.00K. The average tenure of the management team and the board of directors is 3.3 years and 0.8 years respectively.
Key information
Nigel Lange
Chief executive officer
AU$638.6k
Total compensation
| CEO salary percentage | 60.8% |
| CEO tenure | 3.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.3yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky
May 24
Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation
Feb 03Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?
Oct 20OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans
May 13OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years
Mar 21We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn
Jan 26How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?
Dec 04
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$12m |
| Sep 30 2023 | n/a | n/a | -AU$12m |
| Jun 30 2023 | AU$639k | AU$388k | -AU$11m |
| Mar 31 2023 | n/a | n/a | -AU$11m |
| Dec 31 2022 | n/a | n/a | -AU$11m |
| Sep 30 2022 | n/a | n/a | -AU$11m |
| Jun 30 2022 | AU$608k | AU$388k | -AU$11m |
| Mar 31 2022 | n/a | n/a | -AU$11m |
| Dec 31 2021 | n/a | n/a | -AU$11m |
| Sep 30 2021 | n/a | n/a | -AU$11m |
| Jun 30 2021 | AU$964k | AU$359k | -AU$10m |
Compensation vs Market: Nigel's total compensation ($USD425.52K) is above average for companies of similar size in the Australian market ($USD298.11K).
Compensation vs Earnings: Nigel's compensation has increased whilst the company is unprofitable.
CEO
Nigel Lange
3.3yrs
Tenure
AU$638,572
Compensation
Mr. Nigel Lange serves as Chief Executive officer, Managing Director and Director of OncoSil Medical Limited since January 21, 2021. He served as President of EMEA at OncoSil Medical Limited since May 2020...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 3.3yrs | AU$638.57k | 0.24% A$ 40.0k | |
| CFO & Company Secretary | less than a year | no data | no data | |
| Chief Medical Officer | 3.3yrs | no data | no data | |
| Head of Medical Affairs | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
Experienced Management: OSL's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 3.3yrs | AU$638.57k | 0.24% A$ 40.0k | |
| Chairman of the Board | less than a year | no data | no data | |
| Non-Executive Director | less than a year | no data | no data |
0.8yrs
Average Tenure
Experienced Board: OSL's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.